HONG KONG, May 13, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-acting GLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin, while also demonstrating favorable β-cell functional responses.
The study was led by Academician Weiping Jia and co-corresponded by Professor Qinghua Wang, Distinguished Professor of Fudan University, Founder of Innogen Pharmaceuticals, and inventor of Efsubaglutide Alfa. The publication marks another important milestone in the clinical development of Efsubaglutide Alfa and provides further mechanistic insights into its therapeutic value beyond glucose lowering.
SUPER 2 was a randomized, double-blind, placebo-controlled, two-stage adaptive phase IIb/III trial evaluating Efsubaglutide Alfa as add-on therapy to metformin in patients with type 2 diabetes. The results showed that Efsubaglutide Alfa significantly improved HbA1c and other key glycaemic measures, with an overall safety profile consistent with the GLP-1 receptor agonist class, with mainly mild-to-moderate gastrointestinal adverse events.
Importantly, the study went beyond conventional efficacy endpoints and further examined β-cell functional responses using mixed-meal tolerance testing and related metabolic indices. Treatment with Efsubaglutide Alfa was associated with improved postprandial insulin and C-peptide responses, improvement in β-cell function-related parameters, and favorable changes in indices reflecting the integrated relationship between insulin secretion and insulin sensitivity. These findings suggest that the clinical benefit of Efsubaglutide Alfa may extend beyond glycaemic control to partial improvement of the underlying pathophysiology of type 2 diabetes.
This mechanistic signal is particularly meaningful in light of the team's earlier Diabetes Remission study, published in Advances in Therapy, which showed that Efsubaglutide Alfa treatment in drug-naïve patients with type 2 diabetes was associated with remission in a proportion of patients after treatment withdrawal. The SUPER 2 data now provide larger-scale clinical support for the concept that improvement in β-cell function may contribute to the longer-term disease-modifying potential of Efsubaglutide Alfa.
Innogen Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the discovery, development, and translation of novel therapies for diabetes and other metabolic diseases. The publication of SUPER 2 in Nature Communications not only strengthens the clinical evidence base for Efsubaglutide Alfa, but also highlights the value of integrating mechanistic science, clinical development, and translational medicine to advance next-generation therapies for metabolic diseases.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
|
YANGON, Myanmar and KUALA LUMPUR, Malaysia, May 15, 2026 /PRNewswire/ -- Malaysia Healthcare Week Yangon 2026 is officially launched today at Park Royal Yangon, bringing together leading Malaysian hospitals to connect directly with Myanmar patients, healthcare professionals, and industry partners. The four-day initiative, led by the Malaysia Healthcare Travel Council (MHTC), comes amid a 117% increase in the number of Myanmar health tourists who travelled to Malaysia for treatment in 2025.
Held at Park Royal Yangon from 14 to 17 May 2026, the initiative is part of Malaysia's broader efforts under the Malaysia Year of Medical Tourism (MYMT) 2026 campaign, themed Healing Meets Hospitality, which aims to position Malaysia as the preferred global destination for medical tourism.
The event brings together leading Malaysian healthcare providers, including the National Heart Institute (IJN), Subang Jaya Medical Centre, Alpha IVF, Sunway Medical Centre Penang, Prince Court Medical Centre, Pantai Hospital Kuala Lumpur, and KPJ Healthcare Group, showcasing Malaysia's comprehensive range of specialised treatments and patient-centred care.
The initiative comes at a time of rising demand for healthcare services abroad among Myanmar patients. In 2025, the number of health tourists from Myanmar grew by 117%, from 2,901 to 6,285, while the total number of healthcare travellers exceeded 44,000 — reflecting growing confidence in cross-border healthcare and in Malaysia's capabilities as a trusted destination.
MHTC's Chief Executive Officer, Suriaghandi Suppiah, said the initiative reflects Malaysia's long-term commitment to the region.
"Myanmar patients are choosing Malaysia because they trust our clinical standards and the care experience we provide. Malaysia Healthcare Week Yangon is about deepening that trust — connecting patients with our best hospitals and specialists, and building partnerships that ensure seamless, quality care long after the event ends," said Suppiah.
The programme features moderated forums with hospital leaders, insurers, and healthcare administrators; a session addressing embassy officials, expatriate communities, and NGOs; and a Malaysia-Myanmar Clinical Exchange dinner bringing together the medical fraternity from both countries. The weekend's public-facing health expo will offer free consultations and health talks on men's and women's health, wellness, and longevity.
Malaysia Healthcare Week Yangon 2026 is part of a series of regional activations under MYMT 2026. As Malaysia expands its healthcare travel outreach across Southeast Asia, the initiative reinforces the country's position as a trusted long-term healthcare partner — where Healing Meets Hospitality.
For media inquiries and further information, please contact:
Mohamad Shahizam Fauzi
Head, Communications
+603 8776 6168
shahizam.f@mhtc.org.my
Siti Hamidah Mohd Najib
Senior Executive, Communications
+603 8776 6168
hamidah.m@mhtc.org.my
About Malaysia Healthcare Travel Council
Malaysia Healthcare Travel Council (MHTC), established in 2009 under the purview of the Ministry of Health (MOH) Malaysia, is entrusted with developing and nurturing the "Malaysia Healthcare" brand. MHTC enhances, coordinates, and promotes Malaysia's healthcare travel industry by fostering industry collaborations and building valuable public-private partnerships both domestically and internationally. With 80 member hospitals nationwide, MHTC continues to elevate the healthcare travel ecosystem through strong branding, seamless patient experiences, and strategic market initiatives. In line with these efforts, MHTC is spearheading the Malaysia Year of Medical Tourism (MYMT) 2026, the nation's first dedicated year to celebrate and advance healthcare travel. MYMT 2026 serves as a milestone initiative to showcase Malaysia's world-class healthcare offerings, strengthen its position as the premier global healthcare destination, and highlight the industry's significant contribution to the national economy.
More information can be found at https://www.malaysiahealthcare.org.
YANGON, Myanmar and KUALA LUMPUR, Malaysia, May 15, 2026 /PRNewswire/ -- Malaysia Healthcare Week Yangon 2026 is officially launched today at Park Royal Yangon, bringing together leading Malaysian hospitals to connect directly with Myanmar patients, healthcare professionals, and industry partners. The four-day initiative, led by the Malaysia Healthcare Travel Council (MHTC), comes amid a 117% increase in the number of Myanmar health tourists who travelled to Malaysia for treatment in 2025.
Held at Park Royal Yangon from 14 to 17 May 2026, the initiative is part of Malaysia's broader efforts under the Malaysia Year of Medical Tourism (MYMT) 2026 campaign, themed Healing Meets Hospitality, which aims to position Malaysia as the preferred global destination for medical tourism.
The event brings together leading Malaysian healthcare providers, including the National Heart Institute (IJN), Subang Jaya Medical Centre, Alpha IVF, Sunway Medical Centre Penang, Prince Court Medical Centre, Pantai Hospital Kuala Lumpur, and KPJ Healthcare Group, showcasing Malaysia's comprehensive range of specialised treatments and patient-centred care.
The initiative comes at a time of rising demand for healthcare services abroad among Myanmar patients. In 2025, the number of health tourists from Myanmar grew by 117%, from 2,901 to 6,285, while the total number of healthcare travellers exceeded 44,000 — reflecting growing confidence in cross-border healthcare and in Malaysia's capabilities as a trusted destination.
MHTC's Chief Executive Officer, Suriaghandi Suppiah, said the initiative reflects Malaysia's long-term commitment to the region.
"Myanmar patients are choosing Malaysia because they trust our clinical standards and the care experience we provide. Malaysia Healthcare Week Yangon is about deepening that trust — connecting patients with our best hospitals and specialists, and building partnerships that ensure seamless, quality care long after the event ends," said Suppiah.
The programme features moderated forums with hospital leaders, insurers, and healthcare administrators; a session addressing embassy officials, expatriate communities, and NGOs; and a Malaysia-Myanmar Clinical Exchange dinner bringing together the medical fraternity from both countries. The weekend's public-facing health expo will offer free consultations and health talks on men's and women's health, wellness, and longevity.
Malaysia Healthcare Week Yangon 2026 is part of a series of regional activations under MYMT 2026. As Malaysia expands its healthcare travel outreach across Southeast Asia, the initiative reinforces the country's position as a trusted long-term healthcare partner — where Healing Meets Hospitality.
For media inquiries and further information, please contact:
Mohamad Shahizam Fauzi
Head, Communications
+603 8776 6168
shahizam.f@mhtc.org.my
Siti Hamidah Mohd Najib
Senior Executive, Communications
+603 8776 6168
hamidah.m@mhtc.org.my
About Malaysia Healthcare Travel Council
Malaysia Healthcare Travel Council (MHTC), established in 2009 under the purview of the Ministry of Health (MOH) Malaysia, is entrusted with developing and nurturing the "Malaysia Healthcare" brand. MHTC enhances, coordinates, and promotes Malaysia's healthcare travel industry by fostering industry collaborations and building valuable public-private partnerships both domestically and internationally. With 80 member hospitals nationwide, MHTC continues to elevate the healthcare travel ecosystem through strong branding, seamless patient experiences, and strategic market initiatives. In line with these efforts, MHTC is spearheading the Malaysia Year of Medical Tourism (MYMT) 2026, the nation's first dedicated year to celebrate and advance healthcare travel. MYMT 2026 serves as a milestone initiative to showcase Malaysia's world-class healthcare offerings, strengthen its position as the premier global healthcare destination, and highlight the industry's significant contribution to the national economy.
More information can be found at https://www.malaysiahealthcare.org.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Malaysia Healthcare Week Myanmar 2026 Opens in Yangon with Leading Hospitals Showcasing Specialised Care for Myanmar Patients
